GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹5,967 Cr | ₹5,819 Cr | ₹4,546 Cr | ₹4,689 Cr | ₹4,201 Cr |
What is the latest Total Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹5,967 Cr |
| Mar2024 | ₹5,819 Cr |
| Mar2023 | ₹4,546 Cr |
| Mar2022 | ₹4,689 Cr |
| Mar2021 | ₹4,201 Cr |
How is Total Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹5,967 Cr | 2.55 | |
| Mar2024 | ₹5,819 Cr | 27.99 | |
| Mar2023 | ₹4,546 Cr | -3.05 | |
| Mar2022 | ₹4,689 Cr | 11.63 | |
| Mar2021 | ₹4,201 Cr | - | |
Compare Total Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹60,325.9 Cr | 4.9% | 6% | 63.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹417,028.0 Cr | 0.3% | 9% | 8.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹170,237.0 Cr | 1.9% | 5.9% | 12.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹146,801.0 Cr | 0.6% | 9.5% | 45% | Stock Analytics | |
| CIPLA | ₹108,861.0 Cr | 1.6% | 1.8% | -7.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,435.0 Cr | -1.5% | 5.7% | 14.5% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 4.9% |
6% |
63.6% |
| SENSEX | -1.8% |
-1.6% |
7.3% |
You may also like the below Video Courses